The 11 most recent market catalysts affecting $GRAL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Neutral on GRAIL, Raises Price Target to $100
Mizuho analyst Bradley Bowers has maintained a 'Neutral' rating on GRAIL but significantly raised the price target from $65 to $100. This action reflects an updated valuation model…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 55
Baird Maintains Outperform on GRAIL, Raises Price Target to $118
Baird analyst Catherine Schulte has reaffirmed her 'Outperform' rating for GRAIL and raised the price target from $96 to $118. This action signals increased confidence in the compa…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 65
Grail Analyst Sees Massive Market Potential with Valuation Headwinds
RBC Capital Markets initiating coverage on Grail Inc. with a Sector Perform rating and an $84 price target is a significant event for the company, providing institutional validatio…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
GRAIL shares are trading higher after RBC Capital initiated coverage on the stock with a Sector Perform rating and announced an $84 price target.
This headline indicates a significant positive catalyst for GRAIL. Analyst coverage, especially from a reputable firm like RBC Capital, often brings increased investor attention an…
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 55
RBC Capital Initiates Coverage On GRAIL with Sector Perform Rating, Announces Price Target of $84
RBC Capital's initiation of coverage on GRAIL with a 'Sector Perform' rating and an $84 price target provides a new data point for investors. While not a strong 'Buy' or 'Sell' rec…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
UBS Initiates Coverage On GRAIL with Buy Rating, Announces Price Target of $105
UBS analyst Doug Schenkel initiated coverage on GRAIL with a 'Buy' rating and a $105 price target. This is a significant event for GRAIL as it marks the formal entry of a major inv…
Aug 10, 2026
Corporate Catalyst
Neutral
Impact 85
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test
GRAIL's announcement of the FDA advisory committee meeting on September 23 for its Galleri multi-cancer early detection test is a major event. The Galleri test, which has Breakthro…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
GRAIL Q2 EPS $(2.56) Beats $(2.62) Estimate, Sales $44.687M Beat $42.760M Estimate
GRAIL announced its Q2 earnings, reporting a loss of $(2.56) per share, which was better than the analyst consensus of $(2.62). Additionally, the company's sales of $44.687 million…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 55
GRAIL Collaborates With Priority Health To Make GRAIL's Galleri Multi-Cancer Early Detection Test Available To Priority Health's Self-Insured Employer Groups
GRAIL has partnered with Priority Health to offer its Galleri multi-cancer early detection test to Priority Health's self-insured employer groups. This is a significant step for GR…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Neutral on GRAIL, Raises Price Target to $65
Mizuho analyst Bradley Bowers has maintained a 'Neutral' rating on GRAIL but raised the price target from $58 to $65. This action signals a slightly improved valuation perspective …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.